Invitae, a biotech company focusing on genetic testing, laid off 15% of its staff as the company initiated a cost-cutting plan. At the end of 2022, the company had around 1,700 employees. Beyond the ...

Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. The report came ...

Medical genetics company Invitae released a first-of-its-kind data use transparency and impact report today detailing the impact of patient data on genetic research. The report comes as concerns about ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae (NYSE: NVTA) has been one of the most beaten-up stocks this year, falling more than 70% thus far (the S&P 500 has declined by only 10% over the same period). Significant losses and a growth ...

Genetic testing company Invitae has begun making its screening programs available at no charge for conditions including muscular dystrophy, prostate cancer, cardiomyopathy, arrhythmia and lysosomal ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...